Jean-Michel Cossery

EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.

The Association of the British Pharmaceutical Industry is a non-profit organization, which engages in the research and development of medicines. It focuses on biosciences. The company is headquartered in London, the United Kingdom.

Diurnal Group plc engages in the development of products for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. It focuses on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena. The company was founded by Richard John Martin Ross in 2004 and is headquartered in Cardiff, the United Kingdom.

Wipro GE Healthcare Pvt Ltd. is an information technology company that designs and develops medical equipment. The company was founded on March 14, 1990 and is headquartered in Bangalore, India.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Part of Malin Corp. Plc, Malin Life Sciences Holdings Ltd. functions as an investment holding Irish company. The private company is based in Dublin, Ireland. The CEO of the company is George Kelly Martin.

EraCal Therapeutics AG operates as a preclinical biotech company. The firm engages in researching and developing biotechnology. The company was founded by Joshua Jordi in September 2018 and is headquartered in Zollikon, Switzerland.

Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.